Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Published: Dec 23, 2020 SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 7...
United States Hisataka Kobayashi Hiroshi Mikitani Japanese Ministry Of Health National Cancer Institute University Of Texas Md Anderson Cancer Center
Source: biospace.com